Thesis
Dual-BTD psilocybin analog in two Phase 3 pivotals for MDD, but a $42M/quarter burn means survival to NDA hinges on APPROACH data and follow-on financing
Helus Pharma is burning $42.6M per quarter running two simultaneous Phase 3 trials of HLP003, a deuterated psilocybin analog for major depressive disorder, with $157M on hand and no revenue. The thesis resolves on whether APPROACH Phase 3 topline data confirms efficacy sufficient to anchor the 2028 NDA, and whether the company can raise additional capital before cash is exhausted. The central risk is that single-arm or Phase 2-grade precedent does not apply here — HLP003 requires two clean randomized pivotals, and a miss or partial signal on APPROACH would derail both the NDA timeline and financing capacity.
Focus
CYB003 APPROACH Phase 3 topline data
Q4 2026
Bull
A positive APPROACH readout would show statistically significant and clinically meaningful reduction in depression severity (consistent with the Phase 2 MADRS signal) with a clean safety profile and durable effects, validating the dual-BTD psilocybin analog differentiation thesis. This outcome would unlock the follow-on financing pathway, de-risk EMBRACE enrollment, and establish HLP003 as a credible NDA candidate — likely driving a substantial re-rating of the stock and attracting partnership interest.
Bear
The most likely failure modes are a primary endpoint miss on the MADRS or HAMD scale, driven by higher-than-expected placebo response — a persistent problem in MDD trials — or a narrower effect size than Phase 2 suggested, rendering the result non-significant in the larger 223-participant cohort. A safety signal (cardiovascular events, prolonged psychiatric adverse effects, or abuse-potential findings) would be equally damaging, potentially jeopardizing the BTD status and the regulatory pathway entirely.
Unlock the full thesis for HELP.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.